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Summary
The Centers for Disease Control and Prevention (CDC) continues to closely monitor and respond to the COVID-19
outbreak caused by the novel coronavirus, SARS-CoV-2.
This CDC Health Alert Network (HAN) Update highlights guidance and recommendations for evaluating and identifying
patients who should be tested for COVID-19 that were shared on March 4, 2020, on the CDC COVID-19 website at
https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html. It supersedes the guidance and recommendations
provided in CDC’s HAN 428 distributed on February 28, 2020.
The outbreak that began in Wuhan, Hubei Province, has now spread throughout China and to 101 other countries and
territories, including the United States. As of March 8, 2020, there were more than 105,000 cases reported globally. In
addition to sustained transmission in China, there is now community spread in several additional countries. CDC has
updated travel guidance to reflect this information (https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html
As of March 7, 2020, there were a total of 213 cases within the United States, of which, 49 were among repatriated
persons from high-risk settings. Among the other 164 cases that were diagnosed in the United States, 36 were among
persons with a history of recent travel in China or other affected areas, and 18 were persons in close contact with another
confirmed COVID-19 patient (i.e., person-to-person spread); 110 cases are currently under investigation. During the week
of February 23, community spread of the virus that causes COVID-19 was reported in California in two places, Oregon,
and Washington. Community spread in Washington resulted in the first reported case of COVID-19 in a healthcare
worker, and the first outbreak in a long-term care facility. The first death due to COVID-19 was also reported from
Washington; there have now been 11 reported deaths in the U.S. from COVID-19. As of March 7, 2020, COVID-19 cases
had been reported by 19 states. CDC will continue to work with state and local health departments, clinicians, and
laboratorians to identify and respond to other cases of COVID-19, especially those with an unknown source of infection,
to limit further community spread. The most recent update describing COVID-19 in the United States can be found at
https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html.
Recognizing persons who are at risk for COVID-19 is a critical component of identifying cases and preventing further
transmission. With expanding spread of COVID-19, additional areas of geographic risk are being identified and the criteria
for considering testing are being updated to reflect this spread. In addition, with increasing access to testing, the criteria
for testing for COVID-19 have been expanded to include more symptomatic persons, even in the absence of travel history
to affected areas or known exposure to another case, to quickly detect and respond to community spread of the virus in
the United States.
Criteria to Guide Evaluation and Laboratory Testing for COVID-19
Clinicians should work with their local and state health departments to coordinate testing through public health
laboratories. In addition, COVID-19 diagnostic testing, authorized by the Food and Drug Administration under an
Emergency Use Authorization (EUA), is becoming available in clinical laboratories. This additional testing capacity will
allow clinicians to consider COVID-19 testing for a wider group of symptomatic patients.
Clinicians should use their judgment to determine if a patient has signs and symptoms compatible with COVID-19 and
whether the patient should be tested. Most patients with confirmed COVID-19 have developed fever1 and/or symptoms
of acute respiratory illness (e.g., cough, difficulty breathing). Priorities for testing may include:
1. Hospitalized patients who have signs and symptoms compatible with COVID-19 in order to inform decisions related
to infection control.
2. Other symptomatic individuals such as, older adults (age ≥ 65 years) and individuals with chronic medical conditions
and/or an immunocompromised state that may put them at higher risk for poor outcomes (e.g., diabetes, heart
disease, receiving immunosuppressive medications, chronic lung disease, chronic kidney disease).
3. Any persons including healthcare personnel2, who within 14 days of symptom onset had close contact3 with a
suspect or laboratory-confirmed4 COVID-19 patient, or who have a history of travel from affected geographic areas5
(see below) within 14 days of their symptom onset.
There are epidemiologic factors that may also help guide decisions about COVID-19 testing. Documented COVID-19
infections in a jurisdiction and known community transmission may contribute to an epidemiologic risk assessment to
inform testing decisions. Clinicians are strongly encouraged to test for other causes of respiratory illness (e.g., influenza).
Mildly ill patients should be encouraged to stay home and contact their healthcare provider by phone for guidance about
clinical management. Patients who have severe symptoms, such as difficulty breathing, should seek care immediately.
Older patients and individuals who have underlying medical conditions or are immunocompromised should contact their
physician early in the course of even mild illness.
International Areas with Sustained (Ongoing) Transmission
Last updated March 8, 2020
(https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html)
China: Level 3 Travel Health Notice (https://wwwnc.cdc.gov/travel/notices/warning/novel-coronavirus-china)
Iran: Level 3 Travel Health Notice (https://wwwnc.cdc.gov/travel/notices/warning/coronavirus-iran)
Italy: Level 3 Travel Health Notice (https://wwwnc.cdc.gov/travel/notices/warning/coronavirus-italy)
Japan: Level 2 Travel Health Notice (https://wwwnc.cdc.gov/travel/notices/alert/coronavirus-japan)
South Korea: Level 3 Travel Health Notice  (https://wwwnc.cdc.gov/travel/notices/warning/coronavirus-south-korea
Recommendations for Reporting, Laboratory Testing, and Specimen Collection
Clinicians should immediately implement recommended infection prevention and control practices
(https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html) if a patient is suspected
of having COVID-19. They should also notify infection control personnel at their healthcare facility and their state or local
health department if it is suspected that a patient may have COVID-19. State health departments that have identified a
person suspected of having COVID-19 or a laboratory-confirmed case should complete a PUI and Case Report form
through the processes identified on CDC’s Coronavirus Disease 2019 website (https://www.cdc.gov/coronavirus/2019-
ncov/php/reporting-pui.html). If specimens are sent to CDC for laboratory testing, state and local health departments can
contact CDC’s Emergency Operations Center (EOC) at 770-488-7100 for assistance with obtaining, storing, and shipping,
including after hours, on weekends, and holidays.
Guidance for the identification and management of potentially exposed contacts of a confirmed case of COVID-19 can be
found in Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential Coronavirus
Disease 2019 (COVID-19) Exposures: Geographic Risk and Contacts of Laboratory-confirmed Cases
(https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html).
Separate guidance for the management of potentially exposed contacts of a COVID-19 case who are healthcare
personnel is provided in Interim U.S. Guidance for Risk Assessment and Public Health Management of Healthcare
Personnel with Potential Exposure in a Healthcare Setting to Patients with Coronavirus Disease (COVID-19)
(https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html).
For initial diagnostic testing for COVID-19, CDC recommends collecting and testing upper respiratory tract specimens
(nasopharyngeal AND oropharyngeal swabs). CDC also recommends testing lower respiratory tract specimens, if
available. For patients who develop a productive cough, sputum should be collected and tested for SARS-CoV-2. The
induction of sputum is not recommended. For patients for whom it is clinically indicated (e.g., those receiving invasive
mechanical ventilation), a lower respiratory tract aspirate or bronchoalveolar lavage sample should be collected and
tested as a lower respiratory tract specimen. Specimens should be collected as soon as possible once a person has been
identified for testing, regardless of the time of symptom onset. See Interim Guidelines for Collecting, Handling, and
Testing Clinical Specimens from Patients Under Investigation (PUIs) for COVID-19 (https://www.cdc.gov/coronavirus/2019-
nCoV/lab/guidelines-clinical-specimens.html) and Biosafety FAQs for handling and processing specimens from suspected
cases and PUIs (https://www.cdc.gov/coronavirus/2019-ncov/lab/biosafety-faqs.html).
Fever may be subjective or confirmed
For healthcare personnel, testing may be considered if there has been exposure to a person with suspected COVID-19
without laboratory confirmation. Because of their often extensive and close contact with vulnerable patients in
healthcare settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be evaluated among potentially
exposed healthcare personnel. Additional information is available in CDC’s Interim U.S. Guidance for Risk Assessment and
Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting to Patients with
Coronavirus Disease 2019 (COVID-19) (https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-
hcp.html).
Close contact is defined as—
a) being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period; close contact can occur
while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 case
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– or –
b) having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on)
If such contact occurs while not wearing recommended personal protective equipment (PPE) (e.g., gowns, gloves,
NIOSH-certified disposable N95 respirator, eye protection), criteria for PUI consideration are met.
Additional information is available in CDC’s updated Interim Infection Prevention and Control Recommendations for
Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in Healthcare Settings
 (https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html).
Data to inform the definition of close contact are limited. Considerations when assessing close contact include the
duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the
person with COVID-19 (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient).
Special consideration should be given to healthcare personnel exposed in healthcare settings as described in CDC’s
Interim U.S. Guidance for Risk Assessment and Public Health Management of Healthcare Personnel with Potential
Exposure in a Healthcare Setting to Patients with COVID-19 (https://www.cdc.gov/coronavirus/2019-
ncov/hcp/guidance-risk-assesment-hcp.html).
Documentation of laboratory-confirmation of COVID-19 may not be possible for travelers or persons caring for COVID-19
patients in other countries.
Affected areas are defined as geographic regions where sustained community transmission has been identified. For a list
of relevant affected areas, see Coronavirus Disease 2019 Information for Travel (https://www.cdc.gov/coronavirus/2019-
ncov/travelers/index.html).
For More Information
More information is available at the COVID-19 website: https://www.cdc.gov/coronavirus/2019-ncov/index.html.
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The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and
controlling diseases and injuries; enhances health decisions by providing credible information on critical health
issues; and promotes healthy living through strong partnerships with local, national and international organizations.
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HAN Message Types
Health Alert: Conveys the highest level of importance; warrants immediate action or attention.
Health Advisory: Provides important information for a specific incident or situation; may not require immediate
action.
Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate
action.
Info Service: Provides general information that is not necessarily considered to be of an emergent nature.
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